ReviewNature reviews. Neurology2009
Predicting responders to therapies for multiple sclerosis.
Review in Nature reviews. Neurology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 4 syntheses or guidelines pooled it, 125 citations in OpenAlex.
- Metabolomics and metabolites in cancer diagnosis and treatment.Molecular biomedicine · 2025Pooled it
- Pharmacogenetic study of long-term response to interferon-β treatment in multiple sclerosis.The pharmacogenomics journal · 2017Pooled it
- Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients.Nature reviews. Neurology · 2015Guideline
- Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2014Guideline
- Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis.Neurology · 2019Trial
- Trial
- MS lesions are better detected with 3D T1 gradient-echo than with 2D T1 spin-echo gadolinium-enhanced imaging at 3T.AJNR. American journal of neuroradiology · 2015Trial
- Building Towards Initiation, Moderation, De-Escalation and Cessation of Disease-Modifying Treatments for Multiple Sclerosis in Greece: An Expert Panel Consensus Meeting.Brain sciences · 2026Article
- The Variant rs7665090 Is Associated With Interferon-Beta Response in Multiple Sclerosis Patients.European journal of neurology · 2025Article
- Exploring Immune Modulatory Effects of Cyclotide-Enriched Viola tricolor Preparations.Planta medica · 2023Article
- Prognostic models for predicting clinical disease progression, worsening and activity in people with multiple sclerosis.The Cochrane database of systematic reviews · 2023Review
- Metabolomics meets systems immunology.EMBO reports · 2023Review
- Combining Clinical and Genetic Data to Predict Response to Fingolimod Treatment in Relapsing Remitting Multiple Sclerosis Patients: A Precision Medicine Approach.Journal of personalized medicine · 2023Article
- Peripheral myeloid-derived suppressor cells are good biomarkers of the efficacy of fingolimod in multiple sclerosis.Journal of neuroinflammation · 2022Article
- Ipecac root extracts and isolated circular peptides differentially suppress inflammatory immune response characterised by proliferation, activation and degranulation capacity of human lymphocytes in vitro.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Article
- Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial.Multiple sclerosis (Houndmills, Basingstoke, England) · 2022Article
- Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing-remitting multiple sclerosis patients.Journal of neurology · 2022Article
- A Pilot Study of 24-h Motor Activity Patterns in Multiple Sclerosis: Pre-Planned Follow-Up at 2 Years.Clocks & sleep · 2021Article
- Chronic inflammation in multiple sclerosis - seeing what was always there.Nature reviews. Neurology · 2019Review
- Pharmacogenomics of Multiple Sclerosis: A Systematic Review.Frontiers in neurology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Therapies for relapsing-remitting multiple sclerosis (RRMS) are only partially effective, and, in most patients receiving such treatment, clinical activity persists. Accurately assessing the treatment response to disease-modifying agents enables non-responder patients to be identified at an early stage into therapy. Patients can then be switched to another, potentially more effective, therapy before too much neurological damage has occurred. Several criteria based on relapses, disability progression or both have been proposed for clinical evaluation of the treatment response to disease-modifying agents. These criteria have not been independently validated, however, and no consensus over which are the best to use currently exists among investigators. MRI can also be employed to detect disease activity in patients treated with disease-modifying agents. Changes on MRI can provide subclinical data relating to disease activity that can be of great benefit in patients monitoring, as inflammatory events occur more often than clinical events. Pharmacogenomic approaches are in the early stages of development for MS, but hold great promise for the eventual development of individually tailored therapies. In this Review, we discuss the proposed approaches for monitoring and predicting treatment responses to disease-modifying agents in patients with RRMS. We evaluate the roles of clinical measures, MRI and pharmacogenomics in these processes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.